CONMED (CNMD) Financials

$48.49 -2.49 (-4.88%)

Closing price 03:59 PM Eastern

Extended Trading

$49.18 +0.69 (+1.42%)

As of 05:10 PM Eastern

Annual Income Statements for CONMED

This table shows CONMED's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	32	30	15	55	41	29	9.52	63	-81	64	132
Consolidated Net Income / (Loss)	32	30	15	55	41	29	9.52	63	-81	64	132
Net Income / (Loss) Continuing Operations	32	30	15	55	41	29	9.52	63	-81	64	132
Total Pre-Tax Income	47	45	19	29	51	31	1.60	73	-71	81	163
Total Operating Income	53	51	38	47	71	79	46	110	70	121	200
Total Gross Profit	404	382	408	431	469	525	460	568	571	676	733
Total Revenue	740	719	764	796	860	955	862	1,011	1,045	1,245	1,307
Total Cost of Revenue	336	337	355	365	391	430	402	443	474	568	574
Total Operating Expenses	351	331	371	384	398	446	414	458	501	556	533
Selling, General & Admin Expense	323	303	338	352	356	400	374	415	454	503	478
Research & Development Expense	28	27	32	32	42	45	40	44	47	53	54
Total Other Income / (Expense), net	-6.11	-6.03	-18	-18	-21	-48	-44	-37	-141	-40	-37
Interest Expense	6.11	6.03	15	18	21	43	44	35	29	40	37
Other Income / (Expense), net	0.00	0.00	-2.94	0.00	0.00	-5.19	-0.36	-1.13	-112	0.00	0.00
Income Tax Expense	14	15	4.71	-27	9.80	2.61	-7.91	11	9.72	16	31
Basic Earnings per Share	$1.17	$1.10	$0.53	$1.99	$1.45	$1.01	$0.33	$2.14	($2.68)	$2.10	$4.29
Weighted Average Basic Shares Outstanding	27.40M	27.65M	27.80M	27.94M	28.12M	28.49M	28.94M	29.41M	30.50M	30.78M	30.91M
Diluted Earnings per Share	$1.16	$1.09	$0.52	$1.97	$1.41	$0.97	$0.32	$1.94	($2.68)	$2.04	$4.25
Weighted Average Diluted Shares Outstanding	27.40M	27.65M	27.80M	27.94M	28.12M	28.49M	28.94M	29.41M	30.50M	30.78M	30.91M
Weighted Average Basic & Diluted Shares Outstanding	27.40M	27.65M	27.80M	27.94M	28.12M	28.49M	28.94M	29.41M	30.50M	30.78M	30.91M
Cash Dividends to Common per Share	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80

This table shows CONMED's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	46	27	1.82	14	16	33	20	30	49	34
Consolidated Net Income / (Loss)	46	27	1.82	14	16	33	20	30	49	34
Net Income / (Loss) Continuing Operations	46	27	1.82	14	16	33	20	30	49	34
Total Pre-Tax Income	16	-11	2.44	17	20	41	25	38	56	44
Total Operating Income	24	-1.10	13	27	30	50	35	47	66	52
Total Gross Profit	152	132	155	171	168	182	172	184	179	198
Total Revenue	275	251	295	318	305	327	312	332	317	346
Total Cost of Revenue	123	119	140	147	137	145	140	148	138	148
Total Operating Expenses	127	133	143	143	138	132	137	137	113	146
Selling, General & Admin Expense	115	121	130	130	125	118	123	123	100	133
Research & Development Expense	13	12	13	14	12	14	14	14	14	13
Total Other Income / (Expense), net	-8.54	-9.44	-10	-10.00	-10	-9.50	-9.59	-9.59	-9.25	-8.86
Interest Expense	8.54	9.44	10	10.00	10	9.50	9.59	9.59	9.25	8.86
Income Tax Expense	-30	-37	0.63	3.69	4.44	7.61	5.71	7.54	7.47	9.89
Basic Earnings per Share	$1.51	$0.95	$0.06	$0.45	$0.52	$1.07	$0.64	$0.97	$1.59	$1.09
Weighted Average Basic Shares Outstanding	30.47M	30.50M	30.51M	30.66M	30.74M	30.78M	30.78M	30.81M	30.86M	30.91M
Diluted Earnings per Share	$1.48	$1.02	$0.06	$0.43	$0.50	$1.05	$0.63	$0.96	$1.57	$1.09
Weighted Average Diluted Shares Outstanding	31.10M	30.50M	31.20M	31.80M	31.69M	30.78M	31.27M	31.11M	31.11M	30.91M
Weighted Average Basic & Diluted Shares Outstanding	30.48M	30.50M	30.58M	30.74M	30.75M	30.78M	30.80M	30.83M	30.89M	30.91M

This table details how cash moves in and out of CONMED's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	12	6.17	-45	5.19	-15	8.35	1.50	-6.51	8.10	-4.65	0.16
Net Cash From Operating Activities	65	51	40	66	75	95	65	112	33	125	167
Net Cash From Continuing Operating Activities	65	51	40	66	75	95	65	112	33	125	167
Net Income / (Loss) Continuing Operations	32	30	15	55	41	29	9.52	63	-81	64	132
Consolidated Net Income / (Loss)	32	30	15	55	41	29	9.52	63	-81	64	132
Depreciation Expense	20	19	20	20	19	19	18	16	16	16	17
Amortization Expense	26	25	35	38	43	65	68	68	58	62	61
Non-Cash Adjustments To Reconcile Net Income	8.41	3.42	6.49	8.47	14	12	13	20	134	24	38
Changes in Operating Assets and Liabilities, net	-21	-27	-37	-57	-42	-30	-44	-56	-94	-41	-81
Net Cash From Investing Activities	-21	-24	-266	-29	-17	-388	-14	-15	-250	-20	-13
Net Cash From Continuing Investing Activities	-21	-24	-266	-29	-17	-388	-14	-15	-250	-20	-13
Purchase of Property, Plant & Equipment	-15	-15	-15	-13	-17	-20	-13	-15	-22	-19	-13
Acquisitions	-5.27	-9.35	-256	-16	0.00	-368	-3.85	0.00	-228	0.00	0.00
Other Investing Activities, net	-	-	-	-	-	-	-	0.00	0.00	-1.00	0.00
Net Cash From Financing Activities	-26	-13	183	-35	-72	301	-52	-102	225	-110	-151
Net Cash From Continuing Financing Activities	-26	-13	183	-35	-72	301	-52	-102	225	-110	-151
Repayment of Debt	-85	-121	-179	-168	-181	-651	-228	-451	-911	-764	-820
Repurchase of Common Equity	-17	-	-	-	-	-	0.00	0.00	-70	0.00	0.00
Payment of Dividends	-22	-22	-22	-22	-22	-23	-23	-23	-24	-25	-25
Issuance of Debt	113	143	400	155	153	1,002	202	379	1,260	692	751
Issuance of Common Equity	-	-	-	0.00	0.00	31	0.00	0.00	72	0.00	0.00
Other Financing Activities, net	-16	-13	-17	0.00	-21	-58	-2.67	-6.22	-102	-14	-57
Effect of Exchange Rate Changes	-6.22	-7.76	-1.48	3.56	-1.04	-0.01	2.67	-1.87	-0.74	0.47	-2.72
Cash Interest Paid	5.53	5.43	14	16	20	27	30	22	26	34	33
Cash Income Taxes Paid	10	10	9.59	8.87	11	11	9.12	8.56	9.07	20	15

This table details how cash moves in and out of CONMED's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-20	-4.41	-2.45	1.35	2.65	-6.21	9.56	-4.99	9.60	-14
Net Cash From Operating Activities	26	-12	-3.85	27	46	56	29	43	51	43
Net Cash From Continuing Operating Activities	26	-12	-3.85	27	46	56	29	43	51	43
Net Income / (Loss) Continuing Operations	46	27	1.82	14	16	33	20	30	49	34
Consolidated Net Income / (Loss)	46	27	1.82	14	16	33	20	30	49	34
Depreciation Expense	3.94	4.03	4.06	4.17	3.93	4.05	4.05	4.17	4.20	4.20
Amortization Expense	15	15	15	15	15	15	15	15	15	15
Non-Cash Adjustments To Reconcile Net Income	5.75	5.76	5.73	6.42	6.19	5.92	6.24	6.97	6.12	18
Changes in Operating Assets and Liabilities, net	-45	-63	-31	-13	4.69	-2.10	-16	-13	-23	-28
Net Cash From Investing Activities	-91	-6.32	-4.25	-5.53	-5.39	-4.86	-2.04	-3.59	-3.42	-4.04
Net Cash From Continuing Investing Activities	-91	-6.32	-4.25	-5.53	-5.39	-4.86	-2.04	-3.59	-3.42	-4.04
Purchase of Property, Plant & Equipment	-6.71	-5.68	-4.25	-4.53	-5.39	-4.86	-2.04	-3.59	-3.42	-4.04
Net Cash From Financing Activities	47	12	5.35	-20	-37	-59	-17	-44	-39	-51
Net Cash From Continuing Financing Activities	47	12	5.35	-20	-37	-59	-17	-44	-39	-51
Repayment of Debt	-92	-125	-162	-185	-198	-219	-238	-230	-166	-186
Payment of Dividends	-6.09	-6.10	-6.10	-6.11	-6.15	-6.15	-6.15	-6.16	-6.16	-6.18
Issuance of Debt	145	143	173	172	167	180	254	205	142	150
Other Financing Activities, net	-	-0.80	0.00	-	-	-14	-27	-13	-8.66	-8.80
Effect of Exchange Rate Changes	-1.31	1.99	0.30	-0.00	-0.85	1.02	-0.51	-0.62	0.65	-2.24

This table presents CONMED's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	1,098	1,102	1,329	1,358	1,369	1,775	1,752	1,766	2,298	2,300	2,306
Total Current Assets	381	360	331	357	374	397	417	460	581	616	640
Cash & Equivalents	66	73	27	33	18	26	27	21	29	24	24
Accounts Receivable	129	134	148	167	182	189	177	184	191	242	238
Inventories, net	148	133	136	141	155	165	195	232	332	318	347
Prepaid Expenses	22	20	19	16	21	18	17	24	29	31	31
Plant, Property, & Equipment, net	133	125	122	116	113	119	111	109	116	121	116
Total Noncurrent Assets	584	616	876	885	882	1,259	1,224	1,197	1,601	1,564	1,550
Goodwill	256	261	398	402	400	618	618	618	815	807	805
Intangible Assets	316	308	420	415	413	533	502	471	682	649	618
Noncurrent Deferred & Refundable Income Taxes	1.40	4.24	3.71	4.72	5.16	5.66	6.84	9.66	9.65	11	11
Other Noncurrent Operating Assets	9.55	43	56	63	63	102	97	99	94	96	116
Total Liabilities & Shareholders' Equity	1,098	1,102	1,329	1,358	1,369	1,775	1,752	1,766	2,298	2,300	2,306
Total Liabilities	517	517	748	727	707	1,065	1,043	981	1,552	1,466	1,344
Total Current Liabilities	116	120	114	150	161	188	190	197	297	311	278
Short-Term Debt	1.23	1.34	10	15	18	14	18	12	70	0.71	0.72
Accounts Payable	24	35	42	42	53	56	53	58	73	88	102
Current Employee Benefit Liabilities	36	32	32	34	43	54	50	60	55	70	65
Other Current Liabilities	52	52	30	59	46	65	68	66	99	152	110
Total Noncurrent Liabilities	401	397	634	577	546	877	852	784	1,255	1,155	1,065
Long-Term Debt	240	269	488	472	439	755	735	672	985	973	905
Noncurrent Deferred & Payable Income Tax Liabilities	112	103	119	78	81	74	58	69	67	61	74
Other Noncurrent Operating Liabilities	49	24	27	27	26	47	59	43	204	121	86
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	581	585	581	631	662	710	709	785	746	834	963
Total Preferred & Common Equity	581	585	581	631	662	710	709	785	746	834	963
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	581	585	581	631	662	710	709	785	746	834	963
Common Stock	320	325	330	334	342	380	383	397	414	447	477
Retained Earnings	406	415	407	440	465	471	457	497	413	453	560
Treasury Stock	-105	-101	-97	-94	-89	-81	-68	-54	-23	-15	-16
Accumulated Other Comprehensive Income / (Loss)	-40	-54	-59	-49	-56	-59	-64	-54	-58	-50	-59

This table presents CONMED's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	2,292	2,320	2,323	2,326	2,309	2,286	2,316
Total Current Assets	574	610	616	626	636	624	641
Cash & Equivalents	33	26	28	31	34	29	38
Accounts Receivable	197	213	229	230	241	239	231
Inventories, net	305	335	327	326	322	322	343
Prepaid Expenses	39	35	31	39	38	33	29
Plant, Property, & Equipment, net	114	115	117	120	118	117	117
Total Noncurrent Assets	1,604	1,595	1,590	1,580	1,556	1,545	1,557
Goodwill	814	815	816	815	806	806	807
Intangible Assets	689	674	666	657	641	633	626
Other Noncurrent Operating Assets	100	106	109	107	108	105	125
Total Liabilities & Shareholders' Equity	2,292	2,320	2,323	2,326	2,309	2,286	2,316
Total Liabilities	1,576	1,568	1,543	1,529	1,455	1,404	1,383
Total Current Liabilities	209	321	353	376	291	266	282
Short-Term Debt	0.24	70	70	71	0.69	0.72	0.72
Accounts Payable	74	77	79	82	102	101	105
Current Employee Benefit Liabilities	54	49	55	60	50	55	61
Other Current Liabilities	80	125	150	163	139	109	116
Total Noncurrent Liabilities	1,367	1,247	1,189	1,153	1,163	1,137	1,101
Long-Term Debt	1,036	995	971	942	990	965	940
Noncurrent Deferred & Payable Income Tax Liabilities	113	66	66	67	64	65	66
Other Noncurrent Operating Liabilities	218	186	152	144	109	107	95
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	716	752	780	796	855	882	933
Total Preferred & Common Equity	716	752	780	796	855	882	933
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	716	752	780	796	855	882	933
Common Stock	407	420	433	440	458	465	471
Retained Earnings	392	408	416	426	466	490	533
Treasury Stock	-23	-21	-16	-15	-20	-19	-16
Accumulated Other Comprehensive Income / (Loss)	-60	-55	-53	-54	-50	-54	-55

This table displays calculated financial ratios and metrics derived from CONMED's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-2.97%	-2.82%	6.17%	4.31%	7.94%	11.11%	-9.70%	17.18%	3.45%	19.06%	5.00%
EBITDA Growth	-5.61%	-3.52%	-5.27%	17.15%	26.19%	18.70%	-16.65%	46.76%	-83.20%	511.40%	39.97%
EBIT Growth	-6.59%	-3.05%	-32.13%	35.13%	51.92%	3.68%	-38.24%	137.85%	-138.64%	387.44%	66.10%
NOPAT Growth	-9.23%	-5.04%	-17.52%	217.87%	-36.55%	26.09%	276.70%	-65.64%	-47.76%	96.13%	69.18%
Net Income Growth	-10.43%	-5.26%	-51.92%	278.39%	-26.37%	-29.95%	-66.75%	557.16%	-228.84%	179.99%	105.44%
EPS Growth	-9.38%	-6.03%	-52.29%	278.85%	-28.43%	-31.21%	-67.01%	506.25%	-238.14%	176.12%	108.33%
Operating Cash Flow Growth	-19.49%	-21.88%	-21.67%	64.40%	13.93%	27.35%	-32.17%	73.20%	-70.15%	275.69%	33.20%
Free Cash Flow Firm Growth	166.78%	-84.00%	-3,256.86%	123.79%	-27.92%	-779.35%	204.30%	-72.55%	-441.69%	130.69%	22.26%
Invested Capital Growth	-1.44%	3.57%	34.24%	3.20%	1.51%	31.93%	-1.25%	0.97%	22.23%	0.70%	3.38%
Revenue Q/Q Growth	-1.13%	-0.55%	1.74%	2.37%	2.37%	2.40%	-1.38%	2.14%	-2.16%	6.52%	1.47%
EBITDA Q/Q Growth	0.30%	-4.29%	2.47%	12.78%	2.11%	5.75%	-2.86%	5.88%	-82.39%	35.06%	0.82%
EBIT Q/Q Growth	1.75%	-7.45%	-1.03%	29.07%	3.86%	2.40%	-6.06%	11.72%	-138.72%	73.98%	1.17%
NOPAT Q/Q Growth	3.47%	-9.30%	4.66%	207.66%	-43.31%	9.95%	9,444.36%	-11.63%	-35.35%	-29.14%	-0.15%
Net Income Q/Q Growth	3.58%	-10.26%	-7.24%	258.00%	-43.18%	-2.45%	2,960.13%	0.49%	2.59%	11.19%	0.52%
EPS Q/Q Growth	3.57%	-11.38%	-5.45%	251.79%	-44.05%	-3.00%	1,700.00%	-4.90%	9.15%	1.49%	0.95%
Operating Cash Flow Q/Q Growth	-2.49%	-20.90%	3.90%	12.18%	5.50%	20.48%	-24.31%	13.90%	-57.63%	118.55%	-7.25%
Free Cash Flow Firm Q/Q Growth	78.57%	-81.16%	6.49%	72.56%	-42.52%	11.40%	575.97%	-12.41%	-33.87%	9.01%	-3.51%
Invested Capital Q/Q Growth	-2.54%	1.22%	-0.56%	2.97%	1.64%	-0.79%	0.74%	0.66%	3.01%	0.30%	0.48%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.60%	53.08%	53.48%	54.12%	54.57%	54.94%	53.37%	56.21%	54.64%	54.33%	56.08%
EBITDA Margin	13.31%	13.22%	11.79%	13.25%	15.48%	16.54%	15.27%	19.12%	3.11%	15.95%	21.26%
Operating Margin	7.13%	7.12%	4.93%	5.89%	8.29%	8.28%	5.33%	10.86%	6.70%	9.69%	15.33%
EBIT Margin	7.13%	7.12%	4.55%	5.89%	8.29%	7.74%	5.29%	10.74%	-4.01%	9.69%	15.33%
Profit (Net Income) Margin	4.35%	4.24%	1.92%	6.97%	4.75%	3.00%	1.10%	6.19%	-7.71%	5.18%	10.13%
Tax Burden Percent	68.97%	67.56%	75.69%	193.12%	80.65%	91.66%	593.70%	85.55%	113.72%	79.75%	81.23%
Interest Burden Percent	88.42%	88.21%	55.78%	61.22%	71.04%	42.24%	3.51%	67.32%	168.89%	67.02%	81.38%
Effective Tax Rate	31.03%	32.44%	24.31%	-93.12%	19.35%	8.34%	-493.70%	14.45%	0.00%	20.25%	18.77%
Return on Invested Capital (ROIC)	4.78%	4.49%	3.11%	8.48%	5.26%	5.68%	18.91%	6.51%	3.05%	5.41%	8.97%
ROIC Less NNEP Spread (ROIC-NNEP)	2.27%	2.31%	-1.03%	0.88%	1.53%	-1.75%	-16.98%	2.00%	-12.30%	2.20%	5.66%
Return on Net Nonoperating Assets (RNNOA)	0.64%	0.74%	-0.59%	0.67%	1.06%	-1.51%	-17.57%	1.86%	-13.57%	2.75%	5.77%
Return on Equity (ROE)	5.42%	5.23%	2.52%	9.16%	6.32%	4.17%	1.34%	8.37%	-10.53%	8.16%	14.74%
Cash Return on Invested Capital (CROIC)	6.23%	0.99%	-26.13%	5.34%	3.76%	-21.86%	20.17%	5.54%	-16.96%	4.72%	5.65%
Operating Return on Assets (OROA)	4.82%	4.65%	2.86%	3.49%	5.23%	4.70%	2.59%	6.17%	-2.07%	5.25%	8.70%
Return on Assets (ROA)	2.94%	2.77%	1.21%	4.13%	3.00%	1.82%	0.54%	3.56%	-3.97%	2.80%	5.75%
Return on Common Equity (ROCE)	5.42%	5.23%	2.52%	9.16%	6.32%	4.17%	1.34%	8.37%	-10.53%	8.16%	14.74%
Return on Equity Simple (ROE_SIMPLE)	5.54%	5.21%	2.53%	8.79%	6.17%	4.03%	1.34%	7.96%	-10.81%	7.73%	13.76%
Net Operating Profit after Tax (NOPAT)	36	35	29	91	58	73	273	94	49	96	163
NOPAT Margin	4.92%	4.81%	3.73%	11.38%	6.69%	7.59%	31.67%	9.29%	4.69%	7.73%	12.45%
Net Nonoperating Expense Percent (NNEP)	2.51%	2.18%	4.14%	7.60%	3.73%	7.42%	35.89%	4.51%	15.34%	3.21%	3.31%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	2.72%	5.32%	8.71%
Cost of Revenue to Revenue	45.40%	46.92%	46.52%	45.88%	45.43%	45.06%	46.63%	43.79%	45.36%	45.67%	43.92%
SG&A Expenses to Revenue	43.71%	42.14%	44.32%	44.17%	41.37%	41.90%	43.34%	41.04%	43.43%	40.41%	36.59%
R&D to Revenue	3.75%	3.82%	4.22%	4.06%	4.91%	4.76%	4.69%	4.31%	4.51%	4.23%	4.16%
Operating Expenses to Revenue	47.47%	45.96%	48.55%	48.23%	46.28%	46.66%	48.04%	45.35%	47.94%	44.64%	40.76%
Earnings before Interest and Taxes (EBIT)	53	51	35	47	71	74	46	109	-42	121	200
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	99	95	90	105	133	158	132	193	32	199	278
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.91	1.90	1.97	2.13	2.61	4.31	4.40	5.17	3.56	3.99	2.20
Price to Tangible Book Value (P/TBV)	128.74	68.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.50	1.55	1.50	1.69	2.01	3.20	3.62	4.02	2.54	2.68	1.62
Price to Earnings (P/E)	34.50	36.50	77.90	24.25	42.25	106.92	327.84	64.97	0.00	51.69	15.97
Dividend Yield	1.98%	1.99%	1.95%	1.66%	1.30%	0.74%	0.73%	0.58%	0.92%	0.74%	1.17%
Earnings Yield	2.90%	2.74%	1.28%	4.12%	2.37%	0.94%	0.31%	1.54%	0.00%	1.93%	6.26%
Enterprise Value to Invested Capital (EV/IC)	1.70	1.67	1.53	1.66	1.97	2.62	2.68	3.26	2.08	2.40	1.62
Enterprise Value to Revenue (EV/Rev)	1.74	1.82	2.11	2.26	2.52	3.98	4.46	4.68	3.52	3.44	2.29
Enterprise Value to EBITDA (EV/EBITDA)	13.05	13.80	17.92	17.06	16.27	24.07	29.21	24.46	113.32	21.57	10.78
Enterprise Value to EBIT (EV/EBIT)	24.36	25.63	46.45	38.34	30.37	51.44	84.25	43.53	0.00	35.50	14.95
Enterprise Value to NOPAT (EV/NOPAT)	35.31	37.93	56.58	19.85	37.66	52.45	14.08	50.36	75.04	44.52	18.41
Enterprise Value to Operating Cash Flow (EV/OCF)	19.73	25.76	40.45	27.44	28.99	39.98	59.60	42.29	110.29	34.16	17.94
Enterprise Value to Free Cash Flow (EV/FCFF)	27.09	172.68	0.00	31.56	52.68	0.00	13.21	59.13	0.00	51.08	29.23
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.42	0.46	0.86	0.77	0.69	1.08	1.06	0.87	1.41	1.17	0.94
Long-Term Debt to Equity	0.41	0.46	0.84	0.75	0.66	1.06	1.04	0.86	1.32	1.17	0.94
Financial Leverage	0.28	0.32	0.57	0.76	0.69	0.86	1.04	0.93	1.10	1.25	1.02
Leverage Ratio	1.84	1.89	2.09	2.22	2.11	2.29	2.48	2.35	2.65	2.91	2.56
Compound Leverage Factor	1.63	1.66	1.16	1.36	1.50	0.97	0.09	1.58	4.48	1.95	2.09
Debt to Total Capital	29.35%	31.64%	46.20%	43.52%	40.82%	51.97%	51.52%	46.57%	58.59%	53.86%	48.48%
Short-Term Debt to Total Capital	0.15%	0.16%	0.95%	1.31%	1.64%	0.92%	1.26%	0.83%	3.87%	0.04%	0.04%
Long-Term Debt to Total Capital	29.20%	31.48%	45.25%	42.20%	39.19%	51.05%	50.27%	45.74%	54.72%	53.82%	48.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	70.65%	68.36%	53.80%	56.49%	59.18%	48.03%	48.48%	53.43%	41.41%	46.14%	51.52%
Debt to EBITDA	2.45	2.85	5.54	4.61	3.43	4.87	5.72	3.54	32.48	4.91	3.26
Net Debt to EBITDA	1.78	2.09	5.23	4.30	3.30	4.70	5.51	3.43	31.59	4.78	3.17
Long-Term Debt to EBITDA	2.44	2.83	5.42	4.47	3.29	4.78	5.58	3.48	30.34	4.90	3.26
Debt to NOPAT	6.63	7.83	17.48	5.37	7.94	10.60	2.76	7.29	21.51	10.13	5.57
Net Debt to NOPAT	4.81	5.74	16.52	5.01	7.64	10.25	2.66	7.07	20.92	9.87	5.42
Long-Term Debt to NOPAT	6.60	7.79	17.12	5.20	7.63	10.41	2.69	7.16	20.09	10.12	5.56
Altman Z-Score	2.93	2.89	2.20	2.45	2.93	2.91	2.89	3.83	1.82	2.51	2.33
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.29	3.01	2.90	2.38	2.33	2.11	2.19	2.34	1.96	1.98	2.30
Quick Ratio	1.69	1.72	1.54	1.33	1.24	1.14	1.08	1.04	0.74	0.86	0.94
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	47	7.59	-240	57	41	-279	291	80	-273	84	102
Operating Cash Flow to CapEx	422.92%	339.24%	416.51%	510.56%	452.54%	474.10%	659.42%	751.85%	153.16%	658.62%	1,276.12%
Free Cash Flow to Firm to Interest Expense	7.77	1.26	-15.61	3.13	1.99	-6.54	6.61	2.25	-9.45	2.11	2.75
Operating Cash Flow to Interest Expense	10.67	8.44	2.60	3.60	3.62	2.23	1.46	3.15	1.15	3.15	4.48
Operating Cash Flow Less CapEx to Interest Expense	8.14	5.95	1.97	2.90	2.82	1.76	1.24	2.73	0.40	2.67	4.13
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.68	0.65	0.63	0.59	0.63	0.61	0.49	0.57	0.51	0.54	0.57
Accounts Receivable Turnover	5.49	5.47	5.41	5.05	4.93	5.15	4.71	5.60	5.57	5.74	5.45
Inventory Turnover	2.31	2.40	2.64	2.64	2.64	2.70	2.24	2.08	1.68	1.75	1.73
Fixed Asset Turnover	5.43	5.56	6.17	6.69	7.49	8.23	7.49	9.18	9.31	10.53	11.05
Accounts Payable Turnover	13.12	11.54	9.30	8.73	8.17	7.86	7.36	7.94	7.21	7.04	6.03
Days Sales Outstanding (DSO)	66.51	66.78	67.43	72.25	74.00	70.82	77.50	65.20	65.50	63.58	67.02
Days Inventory Outstanding (DIO)	158.25	152.24	138.33	138.52	138.34	135.36	163.13	175.87	217.03	208.87	211.45
Days Payable Outstanding (DPO)	27.81	31.62	39.24	41.81	44.65	46.42	49.59	45.98	50.64	51.88	60.56
Cash Conversion Cycle (CCC)	196.96	187.40	166.53	168.96	167.70	159.77	191.04	195.08	231.89	220.56	217.92
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	756	783	1,052	1,085	1,102	1,453	1,435	1,449	1,771	1,784	1,844
Invested Capital Turnover	0.97	0.93	0.83	0.75	0.79	0.75	0.60	0.70	0.65	0.70	0.72
Increase / (Decrease) in Invested Capital	-11	27	268	34	16	352	-18	14	322	12	60
Enterprise Value (EV)	1,286	1,311	1,613	1,799	2,166	3,803	3,846	4,727	3,680	4,282	2,995
Market Capitalization	1,111	1,113	1,142	1,346	1,726	3,060	3,120	4,063	2,654	3,332	2,114
Book Value per Share	$21.12	$21.12	$20.87	$22.60	$23.54	$25.03	$24.79	$26.86	$24.46	$27.13	$31.16
Tangible Book Value per Share	$0.31	$0.59	($8.50)	($6.64)	($5.38)	($15.52)	($14.37)	($10.36)	($24.66)	($20.23)	($14.90)
Total Capital	823	856	1,079	1,118	1,119	1,479	1,463	1,470	1,800	1,808	1,868
Total Debt	241	271	498	486	457	769	754	685	1,055	974	906
Total Long-Term Debt	240	269	488	472	439	755	735	672	985	973	905
Net Debt	175	198	471	454	439	743	726	664	1,026	950	881
Capital Expenditures (CapEx)	15	15	9.58	13	17	20	9.79	15	22	19	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	200	169	199	189	214	197	218	255	325	281	338
Debt-free Net Working Capital (DFNWC)	266	241	227	221	232	223	245	276	354	306	363
Net Working Capital (NWC)	265	240	217	207	213	209	226	263	285	305	362
Net Nonoperating Expense (NNE)	4.21	4.07	14	35	17	44	264	31	130	32	30
Net Nonoperating Obligations (NNO)	175	198	471	454	439	743	726	664	1,026	950	881
Total Depreciation and Amortization (D&A)	46	44	55	59	62	84	86	85	74	78	78
Debt-free, Cash-free Net Working Capital to Revenue	27.04%	23.49%	26.11%	23.71%	24.92%	20.63%	25.22%	25.22%	31.13%	22.60%	25.87%
Debt-free Net Working Capital to Revenue	36.00%	33.57%	29.70%	27.81%	26.96%	23.34%	28.39%	27.28%	33.90%	24.55%	27.74%
Net Working Capital to Revenue	35.83%	33.38%	28.36%	25.96%	24.83%	21.91%	26.26%	26.07%	27.23%	24.50%	27.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.17	$1.10	$0.53	$1.99	$1.45	$1.01	$0.33	$2.14	($2.68)	$2.10	$4.29
Adjusted Weighted Average Basic Shares Outstanding	27.57M	27.71M	27.84M	27.98M	28.15M	28.49M	28.94M	29.41M	30.50M	30.78M	30.91M
Adjusted Diluted Earnings per Share	$1.16	$1.09	$0.52	$1.97	$1.41	$0.97	$0.32	$1.94	($2.68)	$2.04	$4.25
Adjusted Weighted Average Diluted Shares Outstanding	27.57M	27.71M	27.84M	27.98M	28.15M	28.49M	28.94M	29.41M	30.50M	30.78M	30.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	27.57M	27.71M	27.84M	27.98M	28.15M	28.49M	28.94M	29.41M	30.50M	30.78M	30.91M
Normalized Net Operating Profit after Tax (NOPAT)	36	35	29	33	58	73	32	94	49	96	163
Normalized NOPAT Margin	4.92%	4.81%	3.73%	4.13%	6.69%	7.59%	3.73%	9.29%	4.69%	7.73%	12.45%
Pre Tax Income Margin	6.31%	6.28%	2.54%	3.61%	5.89%	3.27%	0.19%	7.23%	-6.78%	6.49%	12.47%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	8.64	8.49	2.26	2.58	3.45	1.73	1.04	3.06	-1.45	3.03	5.37
NOPAT to Interest Expense	5.96	5.73	1.86	4.98	2.78	1.70	6.20	2.65	1.70	2.42	4.36
EBIT Less CapEx to Interest Expense	6.12	6.00	1.64	1.87	2.65	1.26	0.81	2.64	-2.21	2.55	5.02
NOPAT Less CapEx to Interest Expense	3.44	3.24	1.23	4.27	1.99	1.23	5.98	2.23	0.94	1.94	4.01
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	68.21%	72.48%	151.48%	40.20%	54.93%	78.97%	239.76%	37.18%	-29.73%	38.01%	18.62%
Augmented Payout Ratio	120.59%	72.48%	151.48%	40.20%	54.93%	78.97%	239.76%	37.18%	-116.02%	38.01%	18.62%

This table displays calculated financial ratios and metrics derived from CONMED's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.55%	-8.43%	21.93%	14.60%	10.72%	30.37%	5.69%	4.55%	3.98%	5.78%
EBITDA Growth	-6.15%	-68.76%	-19.96%	167.91%	14.66%	284.02%	69.45%	41.21%	71.21%	3.24%
EBIT Growth	-5.22%	-102.94%	-43.42%	131.32%	24.96%	4,679.01%	175.71%	71.81%	116.85%	4.61%
NOPAT Growth	211.07%	-102.50%	-50.94%	26.23%	-66.78%	5,417.64%	187.23%	74.17%	140.96%	-0.47%
Net Income Growth	208.74%	8.75%	-87.85%	108.16%	-65.68%	24.40%	983.51%	118.29%	209.30%	2.07%
EPS Growth	214.89%	36.00%	-87.23%	107.61%	-66.22%	2.94%	950.00%	123.26%	214.00%	3.81%
Operating Cash Flow Growth	21.21%	-134.33%	-1,272.87%	42.32%	78.14%	586.25%	856.98%	62.36%	11.00%	-23.15%
Free Cash Flow Firm Growth	-2,729.31%	-2,027.08%	-1,015.19%	-7.44%	83.14%	108.81%	102.15%	107.23%	100.76%	-168.98%
Invested Capital Growth	19.44%	22.23%	20.97%	11.91%	3.42%	0.70%	1.15%	1.42%	3.19%	3.38%
Revenue Q/Q Growth	-0.76%	-8.80%	17.78%	7.51%	-4.12%	7.38%	-4.52%	6.35%	-4.64%	9.23%
EBITDA Q/Q Growth	162.67%	-58.15%	77.10%	46.21%	5.81%	40.16%	-21.85%	21.84%	28.29%	-15.48%
EBIT Q/Q Growth	127.70%	-104.52%	1,258.67%	115.91%	10.51%	65.63%	-30.23%	34.54%	39.48%	-20.10%
NOPAT Q/Q Growth	316.00%	-101.08%	1,331.95%	128.66%	9.48%	72.43%	-33.46%	38.65%	51.46%	-28.78%
Net Income Q/Q Growth	127.42%	-42.40%	-93.16%	654.92%	15.33%	108.82%	-40.40%	52.09%	63.41%	-31.09%
EPS Q/Q Growth	126.19%	-31.08%	-94.12%	616.67%	16.28%	110.00%	-40.00%	52.38%	63.54%	-30.57%
Operating Cash Flow Q/Q Growth	38.15%	-144.79%	66.83%	793.35%	72.94%	22.26%	-48.36%	48.71%	18.24%	-15.36%
Free Cash Flow Firm Q/Q Growth	-32.40%	-54.76%	6.79%	43.75%	79.23%	180.87%	-77.27%	89.35%	-97.83%	-7,487.59%
Invested Capital Q/Q Growth	7.31%	3.01%	1.10%	0.14%	-0.83%	0.30%	1.56%	0.40%	0.90%	0.48%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.12%	52.56%	52.57%	53.73%	55.18%	55.70%	55.07%	55.32%	56.52%	57.33%
EBITDA Margin	15.76%	7.23%	10.88%	14.79%	16.32%	21.31%	17.44%	19.98%	26.88%	20.80%
Operating Margin	8.81%	-0.44%	4.30%	8.63%	9.95%	15.35%	11.21%	14.18%	20.75%	15.18%
EBIT Margin	8.81%	-0.44%	4.30%	8.63%	9.95%	15.35%	11.21%	14.18%	20.75%	15.18%
Profit (Net Income) Margin	16.78%	10.60%	0.62%	4.32%	5.20%	10.11%	6.31%	9.03%	15.47%	9.76%
Tax Burden Percent	293.72%	-252.24%	74.43%	78.82%	78.09%	81.29%	77.54%	79.91%	86.77%	77.34%
Interest Burden Percent	64.80%	961.59%	19.25%	63.54%	66.93%	81.06%	72.60%	79.64%	85.92%	83.13%
Effective Tax Rate	-193.72%	0.00%	25.57%	21.18%	21.91%	18.71%	22.46%	20.09%	13.23%	22.66%
Return on Invested Capital (ROIC)	17.51%	-0.20%	2.15%	4.56%	5.19%	8.74%	6.09%	8.01%	12.83%	8.46%
ROIC Less NNEP Spread (ROIC-NNEP)	14.54%	3.04%	1.27%	3.75%	4.40%	7.95%	5.34%	7.22%	11.98%	7.71%
Return on Net Nonoperating Assets (RNNOA)	16.67%	3.35%	1.42%	5.02%	5.78%	9.94%	6.63%	8.47%	13.06%	7.85%
Return on Equity (ROE)	34.18%	3.16%	3.57%	9.58%	10.97%	18.68%	12.72%	16.48%	25.89%	16.31%
Cash Return on Invested Capital (CROIC)	-12.92%	-16.96%	-16.40%	1.89%	4.40%	4.72%	5.15%	5.76%	5.88%	5.65%
Operating Return on Assets (OROA)	4.66%	-0.22%	2.30%	4.47%	5.04%	8.31%	6.11%	7.86%	11.52%	8.61%
Return on Assets (ROA)	8.86%	5.45%	0.33%	2.24%	2.63%	5.48%	3.44%	5.00%	8.59%	5.54%
Return on Common Equity (ROCE)	34.18%	3.16%	3.57%	9.58%	10.97%	18.68%	12.72%	16.48%	25.89%	16.31%
Return on Equity Simple (ROE_SIMPLE)	-11.55%	0.00%	-12.46%	11.32%	7.28%	0.00%	9.64%	11.18%	14.12%	0.00%
Net Operating Profit after Tax (NOPAT)	71	-0.77	9.45	22	24	41	27	38	57	41
NOPAT Margin	25.89%	-0.31%	3.20%	6.80%	7.77%	12.47%	8.69%	11.33%	18.00%	11.74%
Net Nonoperating Expense Percent (NNEP)	2.97%	-3.24%	0.88%	0.81%	0.79%	0.78%	0.75%	0.79%	0.85%	0.75%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.04%	-	-	-	2.26%	-	-	-	2.17%
Cost of Revenue to Revenue	44.88%	47.44%	47.43%	46.27%	44.82%	44.30%	44.93%	44.68%	43.48%	42.67%
SG&A Expenses to Revenue	41.66%	48.13%	44.03%	40.83%	41.14%	36.07%	39.50%	36.89%	31.49%	38.35%
R&D to Revenue	4.64%	4.87%	4.24%	4.27%	4.09%	4.29%	4.35%	4.25%	4.28%	3.81%
Operating Expenses to Revenue	46.30%	53.00%	48.27%	45.10%	45.23%	40.36%	43.86%	41.14%	35.77%	42.16%
Earnings before Interest and Taxes (EBIT)	24	-1.10	13	27	30	50	35	47	66	52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	43	18	32	47	50	70	54	66	85	72
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.36	3.56	4.17	5.28	3.86	3.99	2.87	2.42	2.38	2.20
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.25	2.54	2.85	3.62	2.63	2.68	1.95	1.67	1.72	1.62
Price to Earnings (P/E)	0.00	0.00	0.00	46.66	52.97	51.69	29.82	21.66	16.83	15.97
Dividend Yield	1.01%	0.92%	0.78%	0.59%	0.80%	0.74%	1.00%	1.15%	1.11%	1.17%
Earnings Yield	0.00%	0.00%	0.00%	2.14%	1.89%	1.93%	3.35%	4.62%	5.94%	6.26%
Enterprise Value to Invested Capital (EV/IC)	1.98	2.08	2.33	2.86	2.28	2.40	1.88	1.69	1.70	1.62
Enterprise Value to Revenue (EV/Rev)	3.19	3.52	3.80	4.51	3.47	3.44	2.71	2.41	2.42	2.29
Enterprise Value to EBITDA (EV/EBITDA)	18.49	113.32	30.59	36.49	27.57	21.57	15.45	12.79	11.32	10.78
Enterprise Value to EBIT (EV/EBIT)	31.47	0.00	69.21	81.12	58.47	35.50	23.88	18.89	15.75	14.95
Enterprise Value to NOPAT (EV/NOPAT)	44.96	75.04	98.87	23.01	29.86	44.52	30.10	23.74	19.14	18.41
Enterprise Value to Operating Cash Flow (EV/OCF)	43.31	110.29	142.99	138.26	70.67	34.16	21.56	17.56	17.33	17.94
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	159.63	52.71	51.08	36.82	29.54	29.37	29.23
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.45	1.41	1.42	1.33	1.27	1.17	1.16	1.10	1.01	0.94
Long-Term Debt to Equity	1.45	1.32	1.32	1.25	1.18	1.17	1.16	1.09	1.01	0.94
Financial Leverage	1.15	1.10	1.12	1.34	1.31	1.25	1.24	1.17	1.09	1.02
Leverage Ratio	2.75	2.65	2.66	3.02	3.05	2.91	2.88	2.77	2.68	2.56
Compound Leverage Factor	1.78	25.52	0.51	1.92	2.04	2.36	2.09	2.21	2.31	2.13
Debt to Total Capital	59.14%	58.59%	58.60%	57.16%	55.99%	53.86%	53.69%	52.27%	50.21%	48.48%
Short-Term Debt to Total Capital	0.01%	3.87%	3.83%	3.82%	3.90%	0.04%	0.04%	0.04%	0.04%	0.04%
Long-Term Debt to Total Capital	59.12%	54.72%	54.76%	53.34%	52.08%	53.82%	53.65%	52.24%	50.17%	48.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	40.86%	41.41%	41.40%	42.84%	44.01%	46.14%	46.31%	47.73%	49.79%	51.52%
Debt to EBITDA	5.62	32.48	7.80	7.40	6.89	4.91	4.49	4.02	3.41	3.26
Net Debt to EBITDA	5.44	31.59	7.61	7.20	6.68	4.78	4.33	3.90	3.27	3.17
Long-Term Debt to EBITDA	5.62	30.34	7.29	6.91	6.41	4.90	4.48	4.02	3.41	3.26
Debt to NOPAT	13.67	21.51	25.23	4.67	7.46	10.13	8.74	7.46	5.77	5.57
Net Debt to NOPAT	13.23	20.92	24.60	4.54	7.24	9.87	8.44	7.24	5.54	5.42
Long-Term Debt to NOPAT	13.66	20.09	23.58	4.35	6.94	10.12	8.73	7.46	5.77	5.56
Altman Z-Score	1.85	1.88	2.09	2.52	2.14	2.41	2.07	2.03	2.12	2.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.75	1.96	1.90	1.74	1.66	1.98	2.18	2.34	2.27	2.30
Quick Ratio	1.11	0.74	0.75	0.73	0.69	0.86	0.94	1.01	0.96	0.94
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-209	-323	-301	-169	-35	28	6.46	12	0.27	-20
Operating Cash Flow to CapEx	385.83%	-204.33%	-90.43%	588.94%	855.15%	1,161.59%	1,431.01%	1,206.30%	1,497.60%	1,072.72%
Free Cash Flow to Firm to Interest Expense	-24.45	-34.20	-29.35	-16.94	-3.51	2.99	0.67	1.28	0.03	-2.22
Operating Cash Flow to Interest Expense	3.03	-1.23	-0.38	2.67	4.60	5.93	3.04	4.51	5.53	4.89
Operating Cash Flow Less CapEx to Interest Expense	2.25	-1.83	-0.79	2.22	4.07	5.42	2.82	4.14	5.16	4.44
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.53	0.51	0.54	0.52	0.51	0.54	0.55	0.55	0.56	0.57
Accounts Receivable Turnover	5.89	5.57	5.54	5.28	5.47	5.74	5.55	5.45	5.58	5.45
Inventory Turnover	1.77	1.68	1.72	1.72	1.72	1.75	1.73	1.76	1.71	1.73
Fixed Asset Turnover	9.59	9.31	9.81	9.98	9.98	10.53	10.81	10.91	10.83	11.05
Accounts Payable Turnover	7.84	7.21	7.05	6.94	6.95	7.04	6.38	6.34	6.13	6.03
Days Sales Outstanding (DSO)	61.95	65.50	65.85	69.11	66.76	63.58	65.77	67.00	65.37	67.02
Days Inventory Outstanding (DIO)	205.65	217.03	211.62	212.63	212.10	208.87	211.07	207.98	213.53	211.45
Days Payable Outstanding (DPO)	46.59	50.64	51.78	52.57	52.50	51.88	57.23	57.58	59.56	60.56
Cash Conversion Cycle (CCC)	221.02	231.89	225.70	229.18	226.36	220.56	219.61	217.41	219.34	217.92
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,720	1,771	1,791	1,793	1,778	1,784	1,812	1,819	1,835	1,844
Invested Capital Turnover	0.68	0.65	0.67	0.67	0.67	0.70	0.70	0.71	0.71	0.72
Increase / (Decrease) in Invested Capital	280	322	310	191	59	12	21	25	57	60
Enterprise Value (EV)	3,410	3,680	4,174	5,132	4,053	4,282	3,413	3,072	3,120	2,995
Market Capitalization	2,407	2,654	3,136	4,119	3,071	3,332	2,456	2,135	2,217	2,114
Book Value per Share	$23.51	$24.46	$24.67	$25.52	$25.90	$27.13	$27.77	$28.63	$30.26	$31.16
Tangible Book Value per Share	($25.84)	($24.66)	($24.15)	($22.93)	($22.00)	($20.23)	($19.26)	($18.10)	($16.20)	($14.90)
Total Capital	1,753	1,800	1,817	1,821	1,809	1,808	1,845	1,848	1,874	1,868
Total Debt	1,037	1,055	1,065	1,041	1,013	974	991	966	941	906
Total Long-Term Debt	1,036	985	995	971	942	973	990	965	940	905
Net Debt	1,003	1,026	1,038	1,013	982	950	957	937	902	881
Capital Expenditures (CapEx)	6.71	5.68	4.25	4.53	5.39	4.86	2.04	3.59	3.42	4.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	333	325	333	304	289	281	311	329	321	338
Debt-free Net Working Capital (DFNWC)	366	354	359	332	320	306	345	358	359	363
Net Working Capital (NWC)	366	285	289	262	249	305	344	357	359	362
Net Nonoperating Expense (NNE)	25	-27	7.63	7.88	7.82	7.73	7.44	7.67	8.03	6.85
Net Nonoperating Obligations (NNO)	1,003	1,026	1,038	1,013	982	950	957	937	902	881
Total Depreciation and Amortization (D&A)	19	19	19	20	19	20	19	19	19	19
Debt-free, Cash-free Net Working Capital to Revenue	31.12%	31.13%	30.27%	26.70%	24.77%	22.60%	24.66%	25.80%	24.92%	25.87%
Debt-free Net Working Capital to Revenue	34.24%	33.90%	32.69%	29.15%	27.38%	24.55%	27.35%	28.07%	27.90%	27.74%
Net Working Capital to Revenue	34.22%	27.23%	26.34%	23.03%	21.34%	24.50%	27.29%	28.01%	27.85%	27.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.51	$0.95	$0.06	$0.45	$0.52	$1.07	$0.64	$0.97	$1.59	$1.09
Adjusted Weighted Average Basic Shares Outstanding	30.47M	30.50M	30.51M	30.66M	30.74M	30.78M	30.78M	30.81M	30.86M	30.91M
Adjusted Diluted Earnings per Share	$1.48	$1.02	$0.06	$0.43	$0.50	$1.05	$0.63	$0.96	$1.57	$1.09
Adjusted Weighted Average Diluted Shares Outstanding	31.10M	30.50M	31.20M	31.80M	31.69M	30.78M	31.27M	31.11M	31.11M	30.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.48M	30.50M	30.58M	30.74M	30.75M	30.78M	30.80M	30.83M	30.89M	30.91M
Normalized Net Operating Profit after Tax (NOPAT)	17	-0.77	9.45	22	24	41	27	38	57	41
Normalized NOPAT Margin	6.17%	-0.31%	3.20%	6.80%	7.77%	12.47%	8.69%	11.33%	18.00%	11.74%
Pre Tax Income Margin	5.71%	-4.20%	0.83%	5.48%	6.66%	12.44%	8.14%	11.30%	17.83%	12.62%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.84	-0.12	1.24	2.74	3.02	5.28	3.65	4.91	7.10	5.93
NOPAT to Interest Expense	8.34	-0.08	0.92	2.16	2.36	4.29	2.83	3.92	6.16	4.58
EBIT Less CapEx to Interest Expense	2.05	-0.72	0.82	2.29	2.49	4.77	3.44	4.54	6.73	5.47
NOPAT Less CapEx to Interest Expense	7.56	-0.68	0.51	1.71	1.82	3.78	2.62	3.55	5.79	4.13
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-28.65%	-29.73%	-25.80%	27.63%	42.17%	38.01%	29.82%	24.96%	18.69%	18.62%
Augmented Payout Ratio	-112.71%	-116.02%	-25.80%	27.63%	42.17%	38.01%	29.82%	24.96%	18.69%	18.62%

Frequently Asked Questions About CONMED's Financials

When does CONMED's financial year end?

According to the most recent income statement we have on file, CONMED's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has CONMED's net income changed over the last 10 years?

CONMED's net income appears to be on an upward trend, with a most recent value of $132.42 million in 2024, rising from $32.19 million in 2014. The previous period was $64.46 million in 2023.

What is CONMED's operating income?

CONMED's total operating income in 2024 was $200.33 million, based on the following breakdown:

Total Gross Profit: $733.03 million
Total Operating Expenses: $532.71 million

How has CONMED revenue changed over the last 10 years?

Over the last 10 years, CONMED's total revenue changed from $740.06 million in 2014 to $1.31 billion in 2024, a change of 76.6%.

How much debt does CONMED have?

CONMED's total liabilities were at $1.34 billion at the end of 2024, a 8.3% decrease from 2023, and a 159.9% increase since 2014.

How much cash does CONMED have?

In the past 10 years, CONMED's cash and equivalents has ranged from $17.51 million in 2018 to $72.50 million in 2015, and is currently $24.46 million as of their latest financial filing in 2024.

How has CONMED's book value per share changed over the last 10 years?

Over the last 10 years, CONMED's book value per share changed from 21.12 in 2014 to 31.16 in 2024, a change of 47.6%.

Remove Ads

Related Companies

This page (NYSE:CNMD) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CONMED (CNMD) Financials

Frequently Asked Questions About CONMED's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CONMED (CNMD) Financials

Annual Income Statements for CONMED

Quarterly Income Statements for CONMED

Annual Cash Flow Statements for CONMED

Quarterly Cash Flow Statements for CONMED

Annual Balance Sheets for CONMED

Quarterly Balance Sheets for CONMED

Annual Metrics and Ratios for CONMED

Quarterly Metrics and Ratios for CONMED

Frequently Asked Questions About CONMED's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools